Intramuscular olanzapine vs. intramuscular short-acting antipsychotics

Safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania

R. Chandrasena, D. Dvořáková, S. I. Lee, N. Loza, S. N. Mosolov, P. Osváth, P. Pregelj, R. J. Walton, J. Karagianis, T. Treuer

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: This study compared the safety, tolerability and switch to oral medication in patients with bipolar disorder or schizophrenia who received intramuscular (IM) olanzapine or other IM antipsychotics for the treatment of acute agitation. Methods: Patients (N = 2011) from 15 countries participated in this prospective, observational, non-interventional study. Inpatients requiring treatment with at least one IM injection of a short-acting antipsychotic were assessed at baseline and within 7 days after the first IM injection. Treatment groups comprised: (i) patients prescribed IM olanzapine at baseline; and (ii) patients prescribed any other IM antipsychotic medication at baseline. Outcome measures included: treatment-emergent adverse events, concomitant psychotropic medication and the time taken to switch to oral medication. Results: Fewer patients in the IM olanzapine group experienced an adverse event than patients in the other IM antipsychotic group (34.4% vs. 46.2%, p <0.001). The most frequently reported adverse events in both groups were: sedation, Parkinsonism, disturbance in attention, akathisia, dystonia and orthostatic hypotension. Fewer patients in the IM olanzapine group used anticholinergics (13.9% vs. 42.5%, p <0.001) or anxiolytics/hypnotics (47.6% vs. 51.6%, p = 0.023). Patients in the IM olanzapine group switched to oral medication earlier than patients in the other IM antipsychotic group (median time = 46.5 vs. 48.0 h, p = 0.009). Conclusions: These findings suggest that IM olanzapine may have a favourable impact on individual patients. However, the high rate of oral concomitant medication used throughout the study limits these findings from being associated with IM olanzapine alone.

Original languageEnglish
Pages (from-to)1249-1258
Number of pages10
JournalInternational Journal of Clinical Practice
Volume63
Issue number8
DOIs
Publication statusPublished - Aug 2009

Fingerprint

olanzapine
Bipolar Disorder
Antipsychotic Agents
Schizophrenia
Safety
Intramuscular Injections
Psychomotor Agitation
Orthostatic Hypotension
Dystonia
Anti-Anxiety Agents
Cholinergic Antagonists
Parkinsonian Disorders
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Intramuscular olanzapine vs. intramuscular short-acting antipsychotics : Safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania. / Chandrasena, R.; Dvořáková, D.; Lee, S. I.; Loza, N.; Mosolov, S. N.; Osváth, P.; Pregelj, P.; Walton, R. J.; Karagianis, J.; Treuer, T.

In: International Journal of Clinical Practice, Vol. 63, No. 8, 08.2009, p. 1249-1258.

Research output: Contribution to journalArticle

Chandrasena, R. ; Dvořáková, D. ; Lee, S. I. ; Loza, N. ; Mosolov, S. N. ; Osváth, P. ; Pregelj, P. ; Walton, R. J. ; Karagianis, J. ; Treuer, T. / Intramuscular olanzapine vs. intramuscular short-acting antipsychotics : Safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania. In: International Journal of Clinical Practice. 2009 ; Vol. 63, No. 8. pp. 1249-1258.
@article{ced4d1878f7445efa9006086eb7d000c,
title = "Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: Safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania",
abstract = "Background: This study compared the safety, tolerability and switch to oral medication in patients with bipolar disorder or schizophrenia who received intramuscular (IM) olanzapine or other IM antipsychotics for the treatment of acute agitation. Methods: Patients (N = 2011) from 15 countries participated in this prospective, observational, non-interventional study. Inpatients requiring treatment with at least one IM injection of a short-acting antipsychotic were assessed at baseline and within 7 days after the first IM injection. Treatment groups comprised: (i) patients prescribed IM olanzapine at baseline; and (ii) patients prescribed any other IM antipsychotic medication at baseline. Outcome measures included: treatment-emergent adverse events, concomitant psychotropic medication and the time taken to switch to oral medication. Results: Fewer patients in the IM olanzapine group experienced an adverse event than patients in the other IM antipsychotic group (34.4{\%} vs. 46.2{\%}, p <0.001). The most frequently reported adverse events in both groups were: sedation, Parkinsonism, disturbance in attention, akathisia, dystonia and orthostatic hypotension. Fewer patients in the IM olanzapine group used anticholinergics (13.9{\%} vs. 42.5{\%}, p <0.001) or anxiolytics/hypnotics (47.6{\%} vs. 51.6{\%}, p = 0.023). Patients in the IM olanzapine group switched to oral medication earlier than patients in the other IM antipsychotic group (median time = 46.5 vs. 48.0 h, p = 0.009). Conclusions: These findings suggest that IM olanzapine may have a favourable impact on individual patients. However, the high rate of oral concomitant medication used throughout the study limits these findings from being associated with IM olanzapine alone.",
author = "R. Chandrasena and D. Dvoř{\'a}kov{\'a} and Lee, {S. I.} and N. Loza and Mosolov, {S. N.} and P. Osv{\'a}th and P. Pregelj and Walton, {R. J.} and J. Karagianis and T. Treuer",
year = "2009",
month = "8",
doi = "10.1111/j.1742-1241.2009.02116.x",
language = "English",
volume = "63",
pages = "1249--1258",
journal = "International Journal of Clinical Practice",
issn = "1368-5031",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Intramuscular olanzapine vs. intramuscular short-acting antipsychotics

T2 - Safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania

AU - Chandrasena, R.

AU - Dvořáková, D.

AU - Lee, S. I.

AU - Loza, N.

AU - Mosolov, S. N.

AU - Osváth, P.

AU - Pregelj, P.

AU - Walton, R. J.

AU - Karagianis, J.

AU - Treuer, T.

PY - 2009/8

Y1 - 2009/8

N2 - Background: This study compared the safety, tolerability and switch to oral medication in patients with bipolar disorder or schizophrenia who received intramuscular (IM) olanzapine or other IM antipsychotics for the treatment of acute agitation. Methods: Patients (N = 2011) from 15 countries participated in this prospective, observational, non-interventional study. Inpatients requiring treatment with at least one IM injection of a short-acting antipsychotic were assessed at baseline and within 7 days after the first IM injection. Treatment groups comprised: (i) patients prescribed IM olanzapine at baseline; and (ii) patients prescribed any other IM antipsychotic medication at baseline. Outcome measures included: treatment-emergent adverse events, concomitant psychotropic medication and the time taken to switch to oral medication. Results: Fewer patients in the IM olanzapine group experienced an adverse event than patients in the other IM antipsychotic group (34.4% vs. 46.2%, p <0.001). The most frequently reported adverse events in both groups were: sedation, Parkinsonism, disturbance in attention, akathisia, dystonia and orthostatic hypotension. Fewer patients in the IM olanzapine group used anticholinergics (13.9% vs. 42.5%, p <0.001) or anxiolytics/hypnotics (47.6% vs. 51.6%, p = 0.023). Patients in the IM olanzapine group switched to oral medication earlier than patients in the other IM antipsychotic group (median time = 46.5 vs. 48.0 h, p = 0.009). Conclusions: These findings suggest that IM olanzapine may have a favourable impact on individual patients. However, the high rate of oral concomitant medication used throughout the study limits these findings from being associated with IM olanzapine alone.

AB - Background: This study compared the safety, tolerability and switch to oral medication in patients with bipolar disorder or schizophrenia who received intramuscular (IM) olanzapine or other IM antipsychotics for the treatment of acute agitation. Methods: Patients (N = 2011) from 15 countries participated in this prospective, observational, non-interventional study. Inpatients requiring treatment with at least one IM injection of a short-acting antipsychotic were assessed at baseline and within 7 days after the first IM injection. Treatment groups comprised: (i) patients prescribed IM olanzapine at baseline; and (ii) patients prescribed any other IM antipsychotic medication at baseline. Outcome measures included: treatment-emergent adverse events, concomitant psychotropic medication and the time taken to switch to oral medication. Results: Fewer patients in the IM olanzapine group experienced an adverse event than patients in the other IM antipsychotic group (34.4% vs. 46.2%, p <0.001). The most frequently reported adverse events in both groups were: sedation, Parkinsonism, disturbance in attention, akathisia, dystonia and orthostatic hypotension. Fewer patients in the IM olanzapine group used anticholinergics (13.9% vs. 42.5%, p <0.001) or anxiolytics/hypnotics (47.6% vs. 51.6%, p = 0.023). Patients in the IM olanzapine group switched to oral medication earlier than patients in the other IM antipsychotic group (median time = 46.5 vs. 48.0 h, p = 0.009). Conclusions: These findings suggest that IM olanzapine may have a favourable impact on individual patients. However, the high rate of oral concomitant medication used throughout the study limits these findings from being associated with IM olanzapine alone.

UR - http://www.scopus.com/inward/record.url?scp=67749145751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67749145751&partnerID=8YFLogxK

U2 - 10.1111/j.1742-1241.2009.02116.x

DO - 10.1111/j.1742-1241.2009.02116.x

M3 - Article

VL - 63

SP - 1249

EP - 1258

JO - International Journal of Clinical Practice

JF - International Journal of Clinical Practice

SN - 1368-5031

IS - 8

ER -